98%
921
2 minutes
20
This study investigates the interplay between PD-L1, FOXP3+ regulatory T cells, and CD8+ cytotoxic T lymphocytes in penile squamous cell carcinoma (penile SCC), where understanding the tumor immune microenvironment is crucial. We analyzed 108 penile SCC specimens using tissue microarrays (528 spots). Immunohistochemistry was performed for PD-L1, FOXP3, and CD8. Expression was quantified in tumor and stromal compartments, and correlated with clinicopathological features including histological grade, HPV-associated morphology, and host inflammatory response. PD-L1 in tumor cells positively correlated with intratumoral CD8+ (rho = 0.408, < .001) and FOXP3+ T cells (rho = 0.293, = .009). Peritumoral FOXP3+ and CD8+ T cells also showed a strong correlation (rho = 0.753, < .001). Higher PD-L1 and intratumoral CD8+ were associated with higher histological grade ( < .001). HPV-associated morphology correlated with higher PD-L1 ( < .001) but lower FOXP3+ infiltration ( < .001). Intense inflammatory response was associated with increased peritumoral FOXP3+ and CD8+ T cells ( < .001). The immune microenvironment of penile SCC involves complex interactions among PD-L1, FOXP3+, and CD8+, and was significantly influenced by histological grade, HPV status, and inflammation. The strong co-localization of peritumoral regulatory and cytotoxic T cells suggests a critical regulatory axis. These findings highlight distinct immune profiles within penile SCC, offering insights for developing tailored immunotherapeutic strategies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/10668969251361176 | DOI Listing |
Curr Drug Targets
September 2025
Center for Developmental Biology, School of Life Science, Anhui Agricultural University, 230036, Hefei, China.
Lung cancer, particularly non-small cell lung cancer, is a leading cause of global mortality, with many cases diagnosed at advanced stages. The Toll-Like Receptor (TLR) signaling pathway plays a crucial role in linking inflammation to lung cancer progression, with both pro-tumor and anti-tumor effects. This perspective delves into the complex functions of TLR proteins in lung cancers, elucidating their involvement in tumor growth, angiogenesis, and metastasis.
View Article and Find Full Text PDFInt J Surg Pathol
September 2025
Facultad de Medicina, Universidad del Norte, Asunción, Paraguay.
This study investigates the interplay between PD-L1, FOXP3+ regulatory T cells, and CD8+ cytotoxic T lymphocytes in penile squamous cell carcinoma (penile SCC), where understanding the tumor immune microenvironment is crucial. We analyzed 108 penile SCC specimens using tissue microarrays (528 spots). Immunohistochemistry was performed for PD-L1, FOXP3, and CD8.
View Article and Find Full Text PDFTransl Oncol
August 2025
Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address:
Objectives: Uterine carcinosarcoma (UCS) is an aggressive malignancy characterized by epithelial (C) and mesenchymal (S) components, with complex biology and poor treatment response. This study aims to enhance understanding of UCS through genomic, epigenomic, and transcriptomic analysis.
Methods: Microdissected (C and S) tumor samples were processed for whole-genome sequencing (WGS), RNA-seqencing, and enzymatic methylation sequencing (EM-Seq).
Pharmaceuticals (Basel)
July 2025
Department of Dermatology, University of Alabama at Birmingham, Birmingham, 1670 University Blvd., VH566A, Birmingham, AL 35294, USA.
: This review discusses the resistance mechanisms in the tumor microenvironment (TME) of malignant melanoma that disrupt the efficacy of immune checkpoint inhibitors (ICIs). In this review, we focus on the roles of immune cells, including tumor-infiltrating lymphocytes (TILs), macrophages, dendritic cells, and other signaling pathways. We explore the interplay between innate and adaptive immunity in the TME and tumor intrinsic resistance mechanisms, such as β-catenin, which has future implications for the usage of ICIs in patients with therapy-resistant tumors.
View Article and Find Full Text PDFCancers (Basel)
August 2025
Third Department of Internal Medicine, Sotiria Hospital of Respiratory Diseases, National and Kapodistrian University of Athens, 152 Mesogion Ave, 11527 Athens, Greece.
Immunotherapy with immune checkpoint inhibitors has changed the treatment landscape in many solid tumors. Despite the unprecedent success, many patients will develop primary or secondary resistance to treatment or will hold up therapy due to the emerging immune-related toxicity. Traditionally, tissue-based immune biomarkers, such as PD-L1 expression, have been used to select patients who will benefit most from immunotherapy.
View Article and Find Full Text PDF